drugset
drugset / Trial / NCT02610296

QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant

NCT02610296 ↗

Phase 3 Completed 594 enrolled Quark Pharmaceuticals
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this trial is to evaluate the reduction in incidence and severity of delayed graft function with kidney allografts from donors \>45 years after brain death (DBD).

Timeline

Start
2016-03-01
Primary completion
2018-06-28
Completion
2019-01-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator teprasiran Small interfering RNA (siRNA) — Intravenous

Indications

No indication recorded.